Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

BEERE: a web server for biomedical entity expansion, ranking and explorations.

Yue Z, Willey CD, Hjelmeland AB, Chen JY.

Nucleic Acids Res. 2019 May 22. pii: gkz428. doi: 10.1093/nar/gkz428. [Epub ahead of print]

PMID:
31114876
2.

GC-Recomposition-Olfactometry (GC-R) and multivariate study of three terpenoid compounds in the aroma profile of Angostura bitters.

Johnson AJ, Hjelmeland AK, Heymann H, Ebeler SE.

Sci Rep. 2019 May 21;9(1):7633. doi: 10.1038/s41598-019-44064-y.

3.

Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells.

Wang J, Hjelmeland AB, Nabors LB, King PH.

Cancer Biol Ther. 2019 Apr 16:1-10. doi: 10.1080/15384047.2019.1591673. [Epub ahead of print]

PMID:
30991885
4.

Myristoylated alanine-rich C-kinase substrate effector domain phosphorylation regulates the growth and radiation sensitization of glioblastoma.

Eustace NJ, Anderson JC, Langford CP, Trummell HQ, Hicks PH, Jarboe JS, Mobley JA, Hjelmeland AB, Hackney JR, Pedersen RT, Cosby K, Gillespie GY, Bonner JA, Willey CD.

Int J Oncol. 2019 Jun;54(6):2039-2053. doi: 10.3892/ijo.2019.4766. Epub 2019 Mar 29.

PMID:
30942445
5.

New quantitative approach reveals heterogeneity in mitochondrial structure-function relations in tumor-initiating cells.

Spurlock B, Gupta P, Basu MK, Mukherjee A, Hjelmeland AB, Darley-Usmar V, Parker D, Foxall ME, Mitra K.

J Cell Sci. 2019 May 2;132(9). pii: jcs230755. doi: 10.1242/jcs.230755.

PMID:
30910831
6.

Chromodomain Helicase DNA-Binding Protein 7 Is Suppressed in the Perinecrotic/Ischemic Microenvironment and Is a Novel Regulator of Glioblastoma Angiogenesis.

Boyd NH, Walker K, Ayokanmbi A, Gordon ER, Whetsel J, Smith CM, Sanchez RG, Lubin FD, Chakraborty A, Tran AN, Herting C, Hambardzumyan D, Yancey Gillespie G, Hackney JR, Cooper SJ, Jiao K, Hjelmeland AB.

Stem Cells. 2019 Apr;37(4):453-462. doi: 10.1002/stem.2969. Epub 2019 Jan 24.

PMID:
30629778
7.

IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling.

Oliva CR, Halloran B, Hjelmeland AB, Vazquez A, Bailey SM, Sarkaria JN, Griguer CE.

Cell Commun Signal. 2018 Sep 19;16(1):61. doi: 10.1186/s12964-018-0273-7.

8.

UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts.

Garner EF, Stafman LL, Williams AP, Aye JM, Goolsby C, Atigadda VR, Moore BP, Nan L, Stewart JE, Hjelmeland AB, Friedman GK, Beierle EA.

J Neurooncol. 2018 Nov;140(2):209-224. doi: 10.1007/s11060-018-2950-1. Epub 2018 Aug 21.

PMID:
30132166
9.

Kinomic profiling of glioblastoma cells reveals PLCG1 as a target in restricted glucose.

Walker K, Boyd NH, Anderson JC, Willey CD, Hjelmeland AB.

Biomark Res. 2018 Jun 14;6:22. doi: 10.1186/s40364-018-0136-9. eCollection 2018.

10.

Identification of Compounds That Decrease Glioblastoma Growth and Glucose Uptake in Vitro.

Libby CJ, Zhang S, Benavides GA, Scott SE, Li Y, Redmann M, Tran AN, Otamias A, Darley-Usmar V, Napierala M, Zhang J, Augelli-Szafran CE, Zhang W, Hjelmeland AB.

ACS Chem Biol. 2018 Aug 17;13(8):2048-2057. doi: 10.1021/acschembio.8b00251. Epub 2018 Jun 15.

PMID:
29905460
11.

The ST6Gal-I sialyltransferase protects tumor cells against hypoxia by enhancing HIF-1α signaling.

Jones RB, Dorsett KA, Hjelmeland AB, Bellis SL.

J Biol Chem. 2018 Apr 13;293(15):5659-5667. doi: 10.1074/jbc.RA117.001194. Epub 2018 Feb 23.

12.

Reactive species balance via GTP cyclohydrolase I regulates glioblastoma growth and tumor initiating cell maintenance.

Tran AN, Walker K, Harrison DG, Chen W, Mobley J, Hocevar L, Hackney JR, Sedaka RS, Pollock JS, Goldberg MS, Hambardzumyan D, Cooper SJ, Gillespie Y, Hjelmeland AB.

Neuro Oncol. 2018 Jul 5;20(8):1055-1067. doi: 10.1093/neuonc/noy012.

PMID:
29409010
13.

The pro-tumorigenic effects of metabolic alterations in glioblastoma including brain tumor initiating cells.

Libby CJ, Tran AN, Scott SE, Griguer C, Hjelmeland AB.

Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):175-188. doi: 10.1016/j.bbcan.2018.01.004. Epub 2018 Jan 31. Review.

PMID:
29378228
14.

Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo.

Boyd NH, Walker K, Fried J, Hackney JR, McDonald PC, Benavides GA, Spina R, Audia A, Scott SE, Libby CJ, Tran AN, Bevensee MO, Griguer C, Nozell S, Gillespie GY, Nabors B, Bhat KP, Bar EE, Darley-Usmar V, Xu B, Gordon E, Cooper SJ, Dedhar S, Hjelmeland AB.

JCI Insight. 2017 Dec 21;2(24). pii: 92928. doi: 10.1172/jci.insight.92928.

15.

Modeling Physiologic Microenvironments in Three-Dimensional Microtumors Maintains Brain Tumor Initiating Cells.

Gilbert AN, Walker K, Tran AN, Boyd NH, Gillespie GY, Singh RK, Hjelmeland AB.

J Cancer Stem Cell Res. 2017;5. pii: e1004. doi: 10.14343/JCSCR.2017.5e1004. Epub 2017 Jul 13.

16.

The Arf activator GBF1 localizes to plasma membrane sites involved in cell adhesion and motility.

Busby T, Meissner JM, Styers ML, Bhatt J, Kaushik A, Hjelmeland AB, Sztul E.

Cell Logist. 2017 Mar 20;7(2):e1308900. doi: 10.1080/21592799.2017.1308900. eCollection 2017. No abstract available.

17.

Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells.

Rowse AL, Gibson SA, Meares GP, Rajbhandari R, Nozell SE, Dees KJ, Hjelmeland AB, McFarland BC, Benveniste EN.

J Neurooncol. 2017 Apr;132(2):219-229. doi: 10.1007/s11060-017-2378-z. Epub 2017 Feb 8.

18.

NOS Expression and NO Function in Glioma and Implications for Patient Therapies.

Tran AN, Boyd NH, Walker K, Hjelmeland AB.

Antioxid Redox Signal. 2017 Jun 10;26(17):986-999. doi: 10.1089/ars.2016.6820. Epub 2016 Aug 25. Review.

19.

Metabolic, autophagic, and mitophagic activities in cancer initiation and progression.

Hjelmeland A, Zhang J.

Biomed J. 2016 Apr;39(2):98-106. doi: 10.1016/j.bj.2015.10.002. Epub 2016 Jun 8. Review.

20.

Acute hemodynamic and cardiovascular responses following resistance exercise to voluntary exhaustion. Effects of different loadings and exercise durations.

Gjovaag T, Hjelmeland AK, Oygard JB, Vikne H, Mirtaheri P.

J Sports Med Phys Fitness. 2016 May;56(5):616-23.

PMID:
27285350
21.

A comparison of sorptive extraction techniques coupled to a new quantitative, sensitive, high throughput GC-MS/MS method for methoxypyrazine analysis in wine.

Hjelmeland AK, Wylie PL, Ebeler SE.

Talanta. 2016 Feb 1;148:336-45. doi: 10.1016/j.talanta.2015.10.086. Epub 2015 Oct 30.

PMID:
26653458
22.

A new mitochondrial pool of cyclin E, regulated by Drp1, is linked to cell-density-dependent cell proliferation.

Parker DJ, Iyer A, Shah S, Moran A, Hjelmeland AB, Basu MK, Liu R, Mitra K.

J Cell Sci. 2015 Nov 15;128(22):4171-82. doi: 10.1242/jcs.172429. Epub 2015 Oct 7.

23.
24.

Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells.

Cheng P, Phillips E, Kim SH, Taylor D, Hielscher T, Puccio L, Hjelmeland AB, Lichter P, Nakano I, Goidts V.

Stem Cell Reports. 2015 May 12;4(5):899-913. doi: 10.1016/j.stemcr.2015.03.005. Epub 2015 Apr 23.

25.

Acquisition of meiotic DNA repair regulators maintain genome stability in glioblastoma.

Rivera M, Wu Q, Hamerlik P, Hjelmeland AB, Bao S, Rich JN.

Cell Death Dis. 2015 Apr 23;6:e1732. doi: 10.1038/cddis.2015.75.

26.

Resistance exercise and acute blood pressure responses.

Gjovaag T, Hjelmeland AK, Øygard JB, Vikne H, Mirtaheri P.

J Sports Med Phys Fitness. 2015 Mar 20. [Epub ahead of print]

PMID:
25791757
27.

Development of a Sox2 reporter system modeling cellular heterogeneity in glioma.

Stoltz K, Sinyuk M, Hale JS, Wu Q, Otvos B, Walker K, Vasanji A, Rich JN, Hjelmeland AB, Lathia JD.

Neuro Oncol. 2015 Mar;17(3):361-71. doi: 10.1093/neuonc/nou320. Epub 2014 Nov 21.

28.

A functional screen identifies miRs that induce radioresistance in glioblastomas.

Moskwa P, Zinn PO, Choi YE, Shukla SA, Fendler W, Chen CC, Lu J, Golub TR, Hjelmeland A, Chowdhury D.

Mol Cancer Res. 2014 Dec;12(12):1767-78. doi: 10.1158/1541-7786.MCR-14-0268. Epub 2014 Sep 25.

29.

Phage display discovery of novel molecular targets in glioblastoma-initiating cells.

Liu JK, Lubelski D, Schonberg DL, Wu Q, Hale JS, Flavahan WA, Mulkearns-Hubert EE, Man J, Hjelmeland AB, Yu J, Lathia JD, Rich JN.

Cell Death Differ. 2014 Aug;21(8):1325-39. doi: 10.1038/cdd.2014.65. Epub 2014 May 16.

30.

Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy.

Yan K, Wu Q, Yan DH, Lee CH, Rahim N, Tritschler I, DeVecchio J, Kalady MF, Hjelmeland AB, Rich JN.

Genes Dev. 2014 May 15;28(10):1085-100. doi: 10.1101/gad.235515.113. Epub 2014 May 1.

31.

Microenvironmental variables must influence intrinsic phenotypic parameters of cancer stem cells to affect tumourigenicity.

Scott JG, Hjelmeland AB, Chinnaiyan P, Anderson AR, Basanta D.

PLoS Comput Biol. 2014 Jan;10(1):e1003433. doi: 10.1371/journal.pcbi.1003433. Epub 2014 Jan 16.

32.

High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor.

Lathia JD, Li M, Sinyuk M, Alvarado AG, Flavahan WA, Stoltz K, Rosager AM, Hale J, Hitomi M, Gallagher J, Wu Q, Martin J, Vidal JG, Nakano I, Dahlrot RH, Hansen S, McLendon RE, Sloan AE, Bao S, Hjelmeland AB, Carson CT, Naik UP, Kristensen B, Rich JN.

Cell Rep. 2014 Jan 16;6(1):117-29. doi: 10.1016/j.celrep.2013.11.043. Epub 2013 Dec 27.

33.

Method for Efficient Transduction of Cancer Stem Cells.

Walker K, Hjelmeland A.

J Cancer Stem Cell Res. 2014;2. pii: e1008. Epub 2014 Dec 1.

34.

Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A.

Lotti F, Jarrar AM, Pai RK, Hitomi M, Lathia J, Mace A, Gantt GA Jr, Sukhdeo K, DeVecchio J, Vasanji A, Leahy P, Hjelmeland AB, Kalady MF, Rich JN.

J Exp Med. 2013 Dec 16;210(13):2851-72. doi: 10.1084/jem.20131195. Epub 2013 Dec 9.

35.

Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells.

Venere M, Hamerlik P, Wu Q, Rasmussen RD, Song LA, Vasanji A, Tenley N, Flavahan WA, Hjelmeland AB, Bartek J, Rich JN.

Cell Death Differ. 2014 Feb;21(2):258-69. doi: 10.1038/cdd.2013.136. Epub 2013 Oct 11.

36.

Regional sensory and chemical characteristics of Malbec wines from Mendoza and California.

King ES, Stoumen M, Buscema F, Hjelmeland AK, Ebeler SE, Heymann H, Boulton RB.

Food Chem. 2014 Jan 15;143:256-67. doi: 10.1016/j.foodchem.2013.07.085. Epub 2013 Jul 26.

PMID:
24054238
37.

Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake.

Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, Weil RJ, Nakano I, Sarkaria JN, Stringer BW, Day BW, Li M, Lathia JD, Rich JN, Hjelmeland AB.

Nat Neurosci. 2013 Oct;16(10):1373-82. doi: 10.1038/nn.3510. Epub 2013 Sep 1.

38.

Aptamer identification of brain tumor-initiating cells.

Kim Y, Wu Q, Hamerlik P, Hitomi M, Sloan AE, Barnett GH, Weil RJ, Leahy P, Hjelmeland AB, Rich JN.

Cancer Res. 2013 Aug 1;73(15):4923-36. doi: 10.1158/0008-5472.CAN-12-4556. Epub 2013 Jun 24.

39.

Multiplex flow cytometry barcoding and antibody arrays identify surface antigen profiles of primary and metastatic colon cancer cell lines.

Sukhdeo K, Paramban RI, Vidal JG, Elia J, Martin J, Rivera M, Carrasco DR, Jarrar A, Kalady MF, Carson CT, Balderas R, Hjelmeland AB, Lathia JD, Rich JN.

PLoS One. 2013;8(1):e53015. doi: 10.1371/journal.pone.0053015. Epub 2013 Jan 7.

40.

Laminin alpha 2 enables glioblastoma stem cell growth.

Lathia JD, Li M, Hall PE, Gallagher J, Hale JS, Wu Q, Venere M, Levy E, Rani MR, Huang P, Bae E, Selfridge J, Cheng L, Guvenc H, McLendon RE, Nakano I, Sloan AE, Phillips HS, Lai A, Gladson CL, Bredel M, Bao S, Hjelmeland AB, Rich JN.

Ann Neurol. 2012 Nov;72(5):766-78. doi: 10.1002/ana.23674.

41.

The quest for self-identity: not all cancer stem cells are the same.

Hjelmeland AB, Rich JN.

Clin Cancer Res. 2012 Jul 1;18(13):3495-8. doi: 10.1158/1078-0432.CCR-12-1456. Epub 2012 Jun 18.

42.

Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.

Kim Y, Kim E, Wu Q, Guryanova O, Hitomi M, Lathia JD, Serwanski D, Sloan AE, Weil RJ, Lee J, Nishiyama A, Bao S, Hjelmeland AB, Rich JN.

Genes Dev. 2012 Jun 1;26(11):1247-62. doi: 10.1101/gad.193565.112.

43.

Twisted tango: brain tumor neurovascular interactions.

Hjelmeland AB, Lathia JD, Sathornsumetee S, Rich JN.

Nat Neurosci. 2011 Oct 26;14(11):1375-81. doi: 10.1038/nn.2955. Review.

44.

Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells.

Lathia JD, Gallagher J, Myers JT, Li M, Vasanji A, McLendon RE, Hjelmeland AB, Huang AY, Rich JN.

PLoS One. 2011;6(9):e24807. doi: 10.1371/journal.pone.0024807. Epub 2011 Sep 22.

45.

Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions.

Lathia JD, Hitomi M, Gallagher J, Gadani SP, Adkins J, Vasanji A, Liu L, Eyler CE, Heddleston JM, Wu Q, Minhas S, Soeda A, Hoeppner DJ, Ravin R, McKay RD, McLendon RE, Corbeil D, Chenn A, Hjelmeland AB, Park DM, Rich JN.

Cell Death Dis. 2011 Sep 1;2:e200. doi: 10.1038/cddis.2011.80.

46.

Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential.

Heddleston JM, Wu Q, Rivera M, Minhas S, Lathia JD, Sloan AE, Iliopoulos O, Hjelmeland AB, Rich JN.

Cell Death Differ. 2012 Mar;19(3):428-39. doi: 10.1038/cdd.2011.109. Epub 2011 Aug 12.

47.

Glioma stem cell maintenance: the role of the microenvironment.

Heddleston JM, Hitomi M, Venere M, Flavahan WA, Yang K, Kim Y, Minhas S, Rich JN, Hjelmeland AB.

Curr Pharm Des. 2011;17(23):2386-401. Review.

48.

Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2.

Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL, Lathia JD, Forrester MT, Lee J, Stamler JS, Goldman SA, Bredel M, McLendon RE, Sloan AE, Hjelmeland AB, Rich JN.

Cell. 2011 Jul 8;146(1):53-66. doi: 10.1016/j.cell.2011.06.006.

49.

Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.

Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J, MacSwords J, Eyler CE, McLendon RE, Heddleston JM, Shou W, Hambardzumyan D, Lee J, Hjelmeland AB, Sloan AE, Bredel M, Stark GR, Rich JN, Bao S.

Cancer Cell. 2011 Apr 12;19(4):498-511. doi: 10.1016/j.ccr.2011.03.004.

50.

Molecular targeting of neural cancer stem cells: TTAGGG, you're it!

Hjelmeland AB, Rich JN.

Clin Cancer Res. 2011 Jan 1;17(1):3-5. doi: 10.1158/1078-0432.CCR-10-2686.

Supplemental Content

Loading ...
Support Center